Lupin, one of the leading pharmaceutical companies in India, on March 2 announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S., according to IQVIA MAT December 2020 report. 

 Shares of the company gained Rs 6.25, or 0.59%, to settle  at  Rs 1,060.85.  The total volume of shares traded  was  116,553 at  the BSE (Wednesday).